Lupin Secures EIR From US FDA For its Aurangabad Manufacturing Facility

Lupin Limited, a leading global pharmaceutical company, has secured the Establishment Inspection Report (EIR) from the US Food and Administration (FDA) for its Aurangabad manufacturing facility. The investigation was led from March 6 to March 15, 2024. The facility's inspection classification has been determined to be Voluntary Action Indicated (VAI) by the US FDA. 

“We are pleased to receive the EIR with VAI status from the US FDA as an outcome of the recent inspection of our Aurangabad facility. It is a testament to our commitment to consistently upholding the highest standards of compliance and providing high-quality healthcare solutions to patients worldwide,” said Nilesh Gupta, managing director of Lupin.   Lupin is a development driven transnational drug organization settled in Mumbai, India. The organization creates and popularizes a great many marked and generic formulations, biotechnology items, and APIs in more than 100 business sectors in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The pharmaceutical firm forayed into the diagnostics business in December 2021 to offer an extensive scope of diagnostic tests in India, which incorporates subatomic diagnostics, cytogenetics, flow cytometry, microbial science and serology, among others. Between 2022 and 2025, Lupin intends to enroll over 100 laboratories and 1,000 LupiMitra collection centers across India, of which franchisees will operate 90%.